Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Obesity is defined with reference to hte probable cellular differences in adolescent and maturity-onset obesity. The aetiology and pathogenesis of obesity are briefly discussed. A multifactorial approach was used to treat 263 patients for obesity. This regimen included strict diet, programmed exercise, psychotherapy and medication. D-Phendimetrazine bitartrate in the long-acting form proved an excellent anorexiant for routine use. Fenfluramine was a valuable adjuvant drug for refractory cases. A detailed analysis of the results shows an over-all classified mean weight loss of 14,3%. Interrelationships between degree of overweight, age, degree of weight loss, etc., are critically examined. The most important conclusion was the need for close medical supervision and encouragement both during and after the formal weight loss programme.
 ...
PMID:A review of obesity and its management in 263 cases. 124 22

Specialist physicians may have prescribing habits that are different from nonspecialist physicians. Little is known about the prescribing habits of physicians specializing in the treatment of obesity. An anonymous survey was given to the physician members of the American Society of Bariatric Physicians (ASBP). There was a 35% response rate (266 physicians) to the questionnaire that was represented nationally. Almost all prescribed medications and all of them recommended phentermine. The average maximal dose of phentermine was above that approved in the package insert, and these physicians disagreed with the National Institutes of Health (NIH) Obesity Treatment Guidelines. Phendimetrazine, metformin, and phentermine plus L-5-hydroxytryptophan (5-HTP) with carbidopa were all used more frequently than either orlistat or sibutramine. The combination of sibutramine and orlistat as well as 5-HTP/carbidopa were prescribed by 14 and 20%, respectively. As 5-HTP-carbidopa was a combination not previously reported for the treatment of obesity, a retrospective chart review was performed in a single obesity practice, which may not be representative. Twenty-two subjects had a 16% weight loss with phentermine over 6 months and an additional 1% weight loss with the addition of 5-HTP/carbidopa for an additional 6 months. One subject who started on 5-HTP/carbidopa alone lost 24.4% of initial body weight over 6 months. This questionnaire revealed that 20% of the obesity specialists responding to the survey used phentermine plus of 5-HTP/carbidopa, an unreported combination. A controlled, randomized, clinical trial to evaluate the safety and efficacy of this combination in treating obesity should be considered.
Obesity (Silver Spring) 2009 Sep
PMID:How physician obesity specialists use drugs to treat obesity. 1930 Apr 34